Sinemet (Parkinson’s Disease) - Forecast and Market Analysis to 2022

GlobalData
March 31, 2014
62 Pages - GLDATA18024
$3,495.00

Summary

Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Sinemet (carbidopa and levodopa), developed by Merck & Co., is considered one of the gold standards for treatment in Parkinson’s disease. It is used for the control of motor symptoms in Parkinson’s disease and other Parkinsonian syndromes. Sinemet does not slow the neurodegenerative process in Parkinson’s disease, and over time patients’ responsiveness to therapy may change as they enter more advanced stages of the disease.

Scope

- Overview of Parkinson’s disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Sinemet including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Sinemet for the top eight countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Brazil.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Parkinson’s disease
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Sinemet performance
- Obtain sales forecast for Sinemet from 2012-2022 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Brazil).

'

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 9
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 16
3.1.3 Prognosis 18
3.1.4 Quality of Life 19
3.2 Symptoms 19
4 Disease Management 21
4.1 Overview 21
4.1.1 Diagnosis - The UK Brain Bank Criteria 21
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 22
4.2 Treatment Synopsis 25
4.2.1 Dopaminergic Therapy Classes 25
4.2.2 Treatment of Parkinson’s Disease by Stage 27
4.2.3 Other Treatment Options 30
4.3 Parkinson’s Disease Assessment Scales 30
4.3.1 Unified Parkinson’s Disease Rating Scale (UPDRS) 31
4.3.2 Hoehn and Yahr Clinical Staging 33
4.3.3 Other Clinical Assessments 34
5 Competitive Assessment 35
5.1 Overview 35
5.2 Strategic Competitor Assessment 37
5.3 Product Profiles - Levodopa Combination Therapy 38
6 Sinemet (carbidopa/levodopa) 39
6.1 Overview 39
6.2 Efficacy 41
6.3 Safety 41
6.4 SWOT Analysis 42
6.5 Forecast 42
7 Appendix 45
7.1 Bibliography 45
7.2 Abbreviations 49
7.3 Methodology 52
7.4 Forecasting Methodology 52
7.4.1 Diagnosed Parkinson’s Disease Patients 52
7.4.2 Percent Drug-Treated Patients 53
7.4.3 General Pricing Assumptions 53
7.4.4 Compliance Assumptions 54
7.4.5 Individual Drug Assumptions 55
7.4.6 Generic Erosion 56
7.5 Physicians and Specialists Included in this Study 57
7.6 About the Authors 59
7.6.1 Author 59
7.6.2 Global Head of Healthcare 60
7.7 About GlobalData 61
7.8 Disclaimer 61

1.1 List of Tables
Table 1: Symptoms of Parkinson’s Disease 20
Table 2: UK Brain Bank Diagnostic Criteria 22
Table 3: Diagnosis and Treatment Guidelines for Parkinson’s Disease 23
Table 4: Most Prescribed Drugs for Parkinson’s Disease by Class in the Global Markets, 2014 24
Table 5: Dopaminergic Therapy in Parkinson’s Disease 27
Table 6: UPDRS Clinical Assessment of Disease Severity 32
Table 7: Parkinson’s Disease Assessment Scales Used in Clinical Trials 34
Table 8: Treatment of Motor Symptoms in Parkinson’s Disease 36
Table 9: Leading Treatments for Parkinson’s Disease, 2014 37
Table 10: Product Profile - Sinemet 40
Table 11: Sinemet SWOT Analysis, 2014 42
Table 12: Global Sales Forecasts ($m) for Sinemet, 2012-2022 43
Table 13: Global Sales Forecasts ($m) for Sinemet CR, 2012-2022 44

1.2 List of Figures
Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes 26
Figure 2: Overview - Treatment of Motor Symptoms of Parkinson’s Disease 28

$3,495.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax